ArticleBMJ open2022

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.

Christian Morath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.